Compare MSGY & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGY | TCRT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 6.7M |
| IPO Year | N/A | 2025 |
| Metric | MSGY | TCRT |
|---|---|---|
| Price | $0.57 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 18.0K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.67 |
| 52 Week High | $22.20 | $5.48 |
| Indicator | MSGY | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 40.17 |
| Support Level | $0.41 | $1.92 |
| Resistance Level | $0.60 | $2.84 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 29.55 | 25.51 |
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.